MX385586B - Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia. - Google Patents
Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia.Info
- Publication number
- MX385586B MX385586B MX2017007065A MX2017007065A MX385586B MX 385586 B MX385586 B MX 385586B MX 2017007065 A MX2017007065 A MX 2017007065A MX 2017007065 A MX2017007065 A MX 2017007065A MX 385586 B MX385586 B MX 385586B
- Authority
- MX
- Mexico
- Prior art keywords
- isoindolin
- oxoethyl
- piperidin
- fluorophenyl
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086691P | 2014-12-02 | 2014-12-02 | |
| US201562248071P | 2015-10-29 | 2015-10-29 | |
| PCT/US2015/062985 WO2016089766A1 (en) | 2014-12-02 | 2015-11-30 | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017007065A MX2017007065A (es) | 2017-12-18 |
| MX385586B true MX385586B (es) | 2025-03-18 |
Family
ID=54848909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007065A MX385586B (es) | 2014-12-02 | 2015-11-30 | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia. |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US9458130B2 (OSRAM) |
| EP (2) | EP4063357B1 (OSRAM) |
| JP (4) | JP2018501217A (OSRAM) |
| KR (1) | KR102620681B1 (OSRAM) |
| CN (2) | CN107567444A (OSRAM) |
| AU (4) | AU2015355226B2 (OSRAM) |
| BR (1) | BR112017011555B1 (OSRAM) |
| CA (1) | CA2968977A1 (OSRAM) |
| CL (2) | CL2017001376A1 (OSRAM) |
| CO (1) | CO2017005498A2 (OSRAM) |
| DK (1) | DK3227273T3 (OSRAM) |
| EA (1) | EA201791226A1 (OSRAM) |
| ES (1) | ES2910528T3 (OSRAM) |
| HU (1) | HUE058212T2 (OSRAM) |
| IL (4) | IL313572A (OSRAM) |
| MX (1) | MX385586B (OSRAM) |
| MY (1) | MY185516A (OSRAM) |
| PE (1) | PE20171646A1 (OSRAM) |
| PH (1) | PH12017501007B1 (OSRAM) |
| PL (1) | PL3227273T3 (OSRAM) |
| PT (1) | PT3227273T (OSRAM) |
| SG (1) | SG11201704332YA (OSRAM) |
| TW (1) | TWI694069B (OSRAM) |
| UA (1) | UA122780C2 (OSRAM) |
| WO (1) | WO2016089766A1 (OSRAM) |
| ZA (1) | ZA201703481B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018501217A (ja) * | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| WO2017205393A1 (en) * | 2016-05-25 | 2017-11-30 | Minerva Neurosciences, Inc. | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| PE20200732A1 (es) * | 2017-06-21 | 2020-07-23 | Minerva Neurosciences Inc | Formas de dosificacion oral y de liberacion controlada gastrorresistentes |
| CN107721988A (zh) * | 2017-10-31 | 2018-02-23 | 无锡福祈制药有限公司 | 具有抗炎活性的异吲哚‑1‑酮类化合物 |
| GB2591667A (en) | 2018-08-21 | 2021-08-04 | Minerva Neurosciences Inc | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| TWI841545B (zh) * | 2018-12-12 | 2024-05-11 | 日商田邊三菱製藥股份有限公司 | 耐胃性控制釋放經口劑型 |
| WO2020264486A1 (en) | 2019-06-28 | 2020-12-30 | Teva Czech Industries S.R.O | Solid state forms of roluperidone and salts thereof |
| WO2021236879A1 (en) | 2020-05-20 | 2021-11-25 | The Board Of Trustees Of The University Of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
| CN116251078B (zh) * | 2021-12-09 | 2025-12-19 | 河北以岭医药研究院有限公司 | 一种盐酸度洛西汀肠溶胶囊及其制备方法 |
| EP4479049B1 (en) | 2022-02-14 | 2025-12-17 | Minerva Neurosciences, Inc. | Use of roluperidone in preventing relapse in schizophrenia patients |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ATE102482T1 (de) | 1988-01-21 | 1994-03-15 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit. |
| ZA908641B (en) | 1989-10-27 | 1992-06-24 | Du Pont | (n-phthalimidoalkyl)piperidines |
| FR2797643B1 (fr) | 1999-08-17 | 2003-06-06 | Rhodia Chimie Sa | Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures |
| EP1260512B1 (en) * | 2000-02-29 | 2007-07-04 | Mitsubishi Pharma Corporation | Novel cyclic amide derivatives |
| EP1372611B1 (en) * | 2001-03-26 | 2006-05-17 | Novartis AG | Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer |
| JP5281395B2 (ja) | 2005-06-06 | 2013-09-04 | メルク シャープ エンド ドーム リミテッド | 統合失調症の治療用のｇｌｙｔ１阻害剤としてのシクロヘキサンスルホニル誘導体 |
| CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| DK3135286T3 (da) * | 2010-07-20 | 2023-11-27 | Minerva Neurosciences Inc | Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af skizofreni og symptomer derpå |
| PL2595485T3 (pl) | 2010-07-20 | 2022-06-20 | Minerva Neurosciences, Inc. | Sposoby zastosowania pochodnych amidów cyklicznych w leczeniu zaburzeń mediowanych przez receptor sigma |
| EP2468264A1 (en) | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| AU2012227936A1 (en) * | 2011-03-17 | 2013-10-17 | Lupin Limited | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| JP2018501217A (ja) | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| WO2017205393A1 (en) | 2016-05-25 | 2017-11-30 | Minerva Neurosciences, Inc. | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| PE20200732A1 (es) | 2017-06-21 | 2020-07-23 | Minerva Neurosciences Inc | Formas de dosificacion oral y de liberacion controlada gastrorresistentes |
| GB2591667A (en) | 2018-08-21 | 2021-08-04 | Minerva Neurosciences Inc | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
-
2015
- 2015-11-30 JP JP2017529388A patent/JP2018501217A/ja active Pending
- 2015-11-30 BR BR112017011555-7A patent/BR112017011555B1/pt active IP Right Grant
- 2015-11-30 CN CN201580065471.3A patent/CN107567444A/zh active Pending
- 2015-11-30 DK DK15808314.7T patent/DK3227273T3/da active
- 2015-11-30 PH PH1/2017/501007A patent/PH12017501007B1/en unknown
- 2015-11-30 EP EP22155504.8A patent/EP4063357B1/en active Active
- 2015-11-30 CA CA2968977A patent/CA2968977A1/en active Pending
- 2015-11-30 EP EP15808314.7A patent/EP3227273B1/en active Active
- 2015-11-30 PL PL15808314T patent/PL3227273T3/pl unknown
- 2015-11-30 AU AU2015355226A patent/AU2015355226B2/en active Active
- 2015-11-30 KR KR1020177018088A patent/KR102620681B1/ko active Active
- 2015-11-30 TW TW104139904A patent/TWI694069B/zh active
- 2015-11-30 SG SG11201704332YA patent/SG11201704332YA/en unknown
- 2015-11-30 US US14/954,264 patent/US9458130B2/en active Active
- 2015-11-30 WO PCT/US2015/062985 patent/WO2016089766A1/en not_active Ceased
- 2015-11-30 IL IL313572A patent/IL313572A/en unknown
- 2015-11-30 HU HUE15808314A patent/HUE058212T2/hu unknown
- 2015-11-30 PE PE2017000948A patent/PE20171646A1/es unknown
- 2015-11-30 IL IL301320A patent/IL301320B2/en unknown
- 2015-11-30 MY MYPI2017701998A patent/MY185516A/en unknown
- 2015-11-30 UA UAA201706785A patent/UA122780C2/uk unknown
- 2015-11-30 ES ES15808314T patent/ES2910528T3/es active Active
- 2015-11-30 EA EA201791226A patent/EA201791226A1/ru unknown
- 2015-11-30 CN CN202010012498.9A patent/CN111110677A/zh active Pending
- 2015-11-30 IL IL280052A patent/IL280052B2/en unknown
- 2015-11-30 MX MX2017007065A patent/MX385586B/es unknown
- 2015-11-30 PT PT158083147T patent/PT3227273T/pt unknown
-
2016
- 2016-09-28 US US15/278,421 patent/US9730920B2/en active Active
-
2017
- 2017-05-17 IL IL252347A patent/IL252347B/en active IP Right Grant
- 2017-05-19 ZA ZA2017/03481A patent/ZA201703481B/en unknown
- 2017-05-30 CL CL2017001376A patent/CL2017001376A1/es unknown
- 2017-05-31 CO CONC2017/0005498A patent/CO2017005498A2/es unknown
- 2017-07-17 US US15/651,065 patent/US10258614B2/en active Active
-
2019
- 2019-03-01 US US16/290,234 patent/US10799493B2/en active Active
-
2020
- 2020-06-26 AU AU2020204286A patent/AU2020204286B2/en active Active
- 2020-07-06 JP JP2020116157A patent/JP7069253B2/ja active Active
- 2020-09-11 US US17/017,816 patent/US20210228561A1/en not_active Abandoned
-
2021
- 2021-01-07 CL CL2021000044A patent/CL2021000044A1/es unknown
- 2021-09-10 AU AU2021229240A patent/AU2021229240B2/en active Active
-
2022
- 2022-05-02 JP JP2022076280A patent/JP2022105159A/ja active Pending
-
2023
- 2023-02-17 US US18/111,072 patent/US20230201184A1/en not_active Abandoned
- 2023-11-01 AU AU2023258386A patent/AU2023258386B2/en active Active
-
2024
- 2024-10-02 JP JP2024173051A patent/JP2025004090A/ja active Pending
- 2024-11-27 US US18/961,748 patent/US20250195494A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385586B (es) | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia. | |
| CY1122272T1 (el) | ΕΝΩΣΕΙΣ 3-ΚΥΚΛΟΕΞΕΝΥΛ ΚΑΙ ΚΥΚΛΟΕΞΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΟΥ ΙΝΔΟΛΙΟΥ ΚΑΙ ΙΝΔΑΖΟΛΙΟΥ ΩΣ RORgammaT ΑΝΑΣΤΟΛΕΙΣ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
| CY1118993T1 (el) | Υποκατεστημενες ενωσεις τετραϋδροϊσοκινολινης ως αναστολεις τελεστη xiα | |
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| MX381588B (es) | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| UY35684A (es) | Formulación de inhibidores de la tirosina quinasa de bazo (syk) | |
| CY1119678T1 (el) | Πυριμιδινονες ως αναστολεις τελεστη χια | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| WO2015200680A8 (en) | Prmt5 inhibitors and uses thereof | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| EA202091505A1 (ru) | Триазолазолы циклогексильной кислоты в качестве антагонистов lpa | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| AR103412A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| CO7131360A2 (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| JOP20190129A1 (ar) | تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين | |
| NZ730585A (en) | Indolinone compounds and uses thereof | |
| CO2018001383A2 (es) | Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp” | |
| EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
| CO2017007940A2 (es) | Péptidos antagonistas prgc | |
| CY1121909T1 (el) | Παραγωγο του 4-(3-πυραζολυλαμινο)-βενζιμιδαζολιου ως αναστολεας της jak1 για την αγωγη του καρκινου | |
| MX389403B (es) | Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo |